- Home
- QNTM vs INDP Comparison
QNTM vs INDP Comparison
Compare QNTM & INDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QNTM
- INDP
- Stock Information
- Founded
- QNTM 1998
- INDP 2000
- Country
- QNTM Canada
- INDP United States
- Employees
- QNTM N/A
- INDP N/A
- Industry
- QNTM
- INDP Biotechnology: Pharmaceutical Preparations
- Sector
- QNTM
- INDP Health Care
- Exchange
- QNTM NYSE
- INDP Nasdaq
- Market Cap
- QNTM 9.1M
- INDP 8.8M
- IPO Year
- QNTM N/A
- INDP N/A
- Fundamental
- Price
- QNTM $6.23
- INDP $0.80
- Analyst Decision
- QNTM
- INDP Strong Buy
- Analyst Count
- QNTM 0
- INDP 2
- Target Price
- QNTM N/A
- INDP $8.50
- AVG Volume (30 Days)
- QNTM 7.0M
- INDP 28.5K
- Earning Date
- QNTM 03-31-2025
- INDP 03-12-2025
- Dividend Yield
- QNTM N/A
- INDP N/A
- EPS Growth
- QNTM N/A
- INDP N/A
- EPS
- QNTM N/A
- INDP N/A
- Revenue
- QNTM N/A
- INDP N/A
- Revenue This Year
- QNTM N/A
- INDP N/A
- Revenue Next Year
- QNTM N/A
- INDP N/A
- P/E Ratio
- QNTM N/A
- INDP N/A
- Revenue Growth
- QNTM N/A
- INDP N/A
- 52 Week Low
- QNTM $2.70
- INDP $0.72
- 52 Week High
- QNTM $70.20
- INDP $3.10
- Technical
- Relative Strength Index (RSI)
- QNTM 46.46
- INDP 44.62
- Support Level
- QNTM $10.68
- INDP $0.72
- Resistance Level
- QNTM $12.44
- INDP $0.81
- Average True Range (ATR)
- QNTM 2.41
- INDP 0.07
- MACD
- QNTM -0.42
- INDP -0.00
- Stochastic Oscillator
- QNTM 21.66
- INDP 34.43
About QNTM QUANTUM BIOPHARMA LTD
Quantum BioPharma Ltd formerly FSD Pharma Inc is a biopharmaceutical company developing three clinical candidates with the potential to address neuropsychiatric, neurodegenerative, and inflammatory disorders. Along with its subsidiaries, the group is focused on pharmaceutical research and development of its compound, FSD201, an ultra-micronized PEA, for the treatment of inflammatory diseases; Lucid-Psych is used in the treatment of mental health disorders and Lucid-MS is used in the treatment of neurodegenerative disorders. The company operates in two segments: Biopharmaceutical and Strategic Investments.
About INDP Indaptus Therapeutics Inc.
Indaptus Therapeutics Inc is a pre-clinical biotechnology company engaged in developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. The company's pre-clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma models.